Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

Korábbi kezelés

• Subjects with unresolved lower respiratory tract infection occurring within 6 weeks prior to screening (Visit 1) and/or before enrollment;
• Severe or uncontrolled cardiovascular disease or history, including but not limited to: New York Heart Association (NYHA) functional class III/IV at screening; acute myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to screening; clinically significant arrhythmia requiring intervention or marked QTcF prolongation (male \>450 ms, female \>470 ms) within 3 months prior to screening; or unstable or uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) at screening;
• Concurrent severe, uncontrolled renal, neurological, endocrine, thyroid, urological, ophthalmic, immunological, psychiatric, gastrointestinal, hepatic, or hematological diseases/abnormalities that, in the investigator's judgment, may pose a safety risk to the subject or confound study outcome analysis;
• Use of any protocol-prohibited medication prior to spirometry at screening (Visit 1);
• History of lung lobectomy or lung volume reduction surgery within 12 months prior to screening;
• Major surgery (requiring general anesthesia) within 6 weeks prior to screening with incomplete recovery, or planned surgery before study completion;
• Subjects determined by the investigator to require oxygen therapy;

Más betegség

• History of malignancy (except for carcinoma in situ, cutaneous squamous cell carcinoma, and basal cell carcinoma cured for more than 5 years), suspected malignancy, or undetermined neoplasm;
• Known hypersensitivity to HSK39004 inhalation powder, salbutamol, or any component of the drug delivery system;

Egyéb

• Clinically significant sleep apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV);

• Aged 40 to 80 years (inclusive) at the time of screening visit (Visit 1), male or female;
• Subjects diagnosed with chronic obstructive pulmonary disease (COPD) in accordance with the GOLD 2026 diagnostic criteria prior to screening \[GOLD 2026 criteria: presence of chronic respiratory symptoms such as dyspnea, chronic cough or sputum production, and/or a history of risk factor exposure, and the pulmonary function test results show: the forced expiratory volume in one second (FEV1) after using bronchodilators / forced vital capacity (FVC) \<0.7\];
• At screening visit (Visit 1):
  • Post-bronchodilator FEV1/FVC \< 0.7; and
  • Post-bronchodilator FEV1 ≥ 30% and \< 80% of predicted value;
• Modified Medical Research Council (mMRC) dyspnea scale score ≥ 2 at screening;